Key Highlights

  • Aurinia shares edged down 0.41% to $14.83, against a prior close of $14.89.
  • RBC raised its price target to $18, and TD Cowen holds an $18 target.
  • The consensus price target is near $17.33.
  • Third-quarter EPS was $0.23 on Revenue of $83.7 million.
  • The stock trades below its 50-day average of about $16.41.

Aurinia Holds Steady While Targets Cluster at $18

Aurinia Pharmaceuticals (NASDAQ:AUPH) shares edged down 0.41% to $14.83 on Friday, with Volume of about 509,740 shares, below average. The biotechnology company's stock has been quiet even as the broader market turned volatile.

RBC raised its price target to $18 with a sector perform rating, and TD Cowen holds an $18 target with a buy rating. The consensus price target sits near $17.33, and the consensus rating is Moderate Buy.

Below the 50-Day Average and Near the Bottom of the 12-Month Range

The shares trade below their 50-day average of about $16.41 and near the low end of a 12-month range of $13.52 to $19.25. Two independent ratings services trimmed their ratings in early November.

A form filed on Nov. 13 showed an automatic tax-withholding sale of 11,867 shares at about $15.97 by the Chief Legal Officer.

Solid Quarter and a Low Multiple, With Biotech Peers Mostly Lower

In its third quarter, Aurinia reported Earnings Per Share of $0.23 on revenue of $83.7 million, a modest beat. The stock trades at about 6.48 times trailing earnings on earnings per share of $1.02, and pays no dividend.

Biotech peers were mostly lower. Protagonist Therapeutics (NASDAQ:PTGX) fell 1.15%, ImmunityBio (NASDAQ:IBRX) dropped 7.31%, TG Therapeutics (NASDAQ:TGTX) slipped 0.80% and Arrowhead Pharmaceuticals (NASDAQ:ARWR) declined 2.30%. A reported Takeover approach elsewhere in the sector has added to Merger speculation.

Whether the Stock Can Reclaim Its 50-Day Average Is the Next Question

Aurinia's session was flat, with analyst targets clustered near $17 to $18 and shares well below that level. Investors will watch whether the stock can move back toward its 50-day average and how targets evolve after the quarterly report.